Improving Transplant Medication Safety Through a Technology and Pharmacist Intervention (ISTEP): Protocol for a Cluster Randomized Controlled Trial

Casey L Hall, Cory E Fominaya, Mulugeta Gebregziabher, Sherry K Milfred-LaForest, Kelsey M Rife, David J Taber, Casey L Hall, Cory E Fominaya, Mulugeta Gebregziabher, Sherry K Milfred-LaForest, Kelsey M Rife, David J Taber

Abstract

Background: Medication errors, adverse drug events, and nonadherence lead to increased health care utilization and increased risk of adverse clinical outcomes, including graft loss, in solid organ transplant recipients. Veterans living with organ transplants represent a population that is at substantial risk for medication safety events and fragmented care coordination issues. To improve medication safety and long-term clinical outcomes in veteran transplant patients, interventions should address interorganizational system failures and provider-level and patient-level factors.

Objective: This study aims to measure the clinical and economic effectiveness of a pharmacist-led, technology-enabled intervention, compared with usual care, in veteran organ transplant recipients.

Methods: This is a 24-month prospective, parallel-arm, cluster-randomized, controlled multicenter study. The pharmacist-led intervention uses an innovative dashboard system to improve medication safety and health outcomes, compared with usual posttransplant care. Pharmacists at 10 study sites will be consented into this study before undergoing randomization, and 5 sites will then be randomized to each study arm. Approximately, 1600 veteran transplant patients will be included in the assessment of the primary outcome across the 10 sites.

Results: This study is ongoing. Institutional review board approval was received in October 2018 and the study opened in March 2019. To date there are no findings from this study, as the delivery of the intervention is scheduled to occur over a 24-month period. The first results are expected to be submitted for publication in August 2021.

Conclusions: With this report, we describe the study design, methods, and outcome measures that will be used in this ongoing clinical trial. Successful completion of the Improving Transplant Medication Safety through a Technology and Pharmacist Intervention study will provide empirical evidence of the effectiveness of a feasible and scalable technology-enabled intervention on improving medication safety and costs.

Clinical trial: ClinicalTrials.gov NCT03860818; https://ichgcp.net/clinical-trials-registry/NCT03860818.

International registered report identifier (irrid): PRR1-10.2196/13821.

Keywords: adherence; medication adherence; medication errors; transplant.

Conflict of interest statement

Conflicts of Interest: None declared.

©Casey L Hall, Cory E Fominaya, Mulugeta Gebregziabher, Sherry K Milfred-LaForest, Kelsey M Rife, David J Taber. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 01.10.2019.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6774238/bin/resprot_v8i10e13821_fig1.jpg
Schematic representation of the process the pharmacist will use to identify, manage, and resolve potential medication safety issues.

References

    1. Matas AJ, Smith JM, Skeans MA, Lamb KE, Gustafson SK, Samana CJ, Stewart DE, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2011 annual data report: kidney. Am J Transplant. 2013 Jan;13(Suppl 1):11–46. doi: 10.1111/ajt.12019. doi: 10.1111/ajt.12019.
    1. Meier-Kriesche H, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004 Mar;4(3):378–83. doi: 10.1111/j.1600-6143.2004.00332.x.
    1. Sellarés J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012 Feb;12(2):388–99. doi: 10.1111/j.1600-6143.2011.03840.x. doi: 10.1111/j.1600-6143.2011.03840.x.
    1. Dobbels F, de Geest S, van Cleemput J, Droogne W, Vanhaecke J. Effect of late medication non-compliance on outcome after heart transplantation: a 5-year follow-up. J Heart Lung Transplant. 2004 Nov;23(11):1245–51. doi: 10.1016/j.healun.2003.09.016.
    1. Serper M, Patzer RE, Reese PP, Przytula K, Koval R, Ladner DP, Levitsky J, Abecassis MM, Wolf MS. Medication misuse, nonadherence, and clinical outcomes among liver transplant recipients. Liver Transpl. 2015 Jan;21(1):22–8. doi: 10.1002/lt.24023. doi: 10.1002/lt.24023.
    1. Friedman AL, Geoghegan SR, Sowers NM, Kulkarni S, Formica RN. Medication errors in the outpatient setting: classification and root cause analysis. Arch Surg. 2007 Mar;142(3):278–83; discussion 284. doi: 10.1001/archsurg.142.3.278.
    1. Irani S, Seba P, Speich R, Boehler A. Medication errors: an important component of nonadherence to medication in an outpatient population of lung transplant recipients. Am J Transplant. 2007 Nov;7(11):2561–6. doi: 10.1111/j.1600-6143.2007.01962.x. doi: 10.1111/j.1600-6143.2007.01962.x.
    1. Taber DJ, Pilch NA, Bratton CF, McGillicuddy JW, Chavin KD, Baliga PK. Medication errors and adverse drug events in kidney transplant recipients: incidence, risk factors, and clinical outcomes. Pharmacotherapy. 2012 Dec;32(12):1053–60. doi: 10.1002/phar.1145.
    1. Taber DJ, Spivey JR, Tsurutis VM, Pilch NA, Meadows HB, Fleming JN, McGillicuddy JW, Bratton CF, Treiber FA, Baliga PK, Chavin KD. Clinical and economic outcomes associated with medication errors in kidney transplantation. Clin J Am Soc Nephrol. 2014 May;9(5):960–6. doi: 10.2215/CJN.09300913.
    1. Samal L, Bates DW. To err is human: lessons from patient safety research for transplant care. Clin J Am Soc Nephrol. 2014 May;9(5):845–7. doi: 10.2215/CJN.02850314.
    1. Thrall SA, Egede LE, Taber DJ. Ambulatory care coordination issues with dual use veteran organ transplant recipients. Prog Transplant. 2017 Jun;27(2):187–91. doi: 10.1177/1526924817699963.
    1. Elhauge E, editor. The Fragmentation of US Health Care: Causes and Solutions. New York: Oxford University Press on Demand; 2010.
    1. Hempstead K, Delia D, Cantor JC, Nguyen T, Brenner J. The fragmentation of hospital use among a cohort of high utilizers: implications for emerging care coordination strategies for patients with multiple chronic conditions. Med Care. 2014 Mar;52(Suppl 3):S67–74. doi: 10.1097/MLR.0000000000000049.
    1. Frandsen BR, Joynt KE, Rebitzer JB, Jha AK. Care fragmentation, quality, and costs among chronically ill patients. Am J Manag Care. 2015 Jul 21;21(5):355–62.
    1. Department of Veterans Affairs. 2009. Feb, [2016-12-05]. VHA National Dual Care Policy: VHA Directive 2009-038 .
    1. Petersen LA, Byrne MM, Daw CN, Hasche J, Reis B, Pietz K. Relationship between clinical conditions and use of veterans affairs health care among medicare-enrolled veterans. Health Serv Res. 2010;45(3):762–91. doi: 10.1111/j.1475-6773.2010.01107.x.
    1. Hester EJ, Cook DJ, Robbins LJ. The VA and medicare HMOs — complementary or redundant? N Engl J Med. 2005 Sep 22;353(12):1302–3. doi: 10.1056/NEJMc051890.
    1. Gellad WF. The veterans choice act and dual health system use. J Gen Intern Med. 2015 Aug 20;31(2):153–4. doi: 10.1007/s11606-015-3492-2.
    1. Axon RN, Gebregziabher M, Everett CJ, Heidenreich P, Hunt KJ. Dual health care system use is associated with higher rates of hospitalization and hospital readmission among veterans with heart failure. Am Heart J. 2016 Apr 7;174:157–63. doi: 10.1016/j.ahj.2015.09.023.
    1. Jia H, Zheng Y, Reker DM, Cowper DC, Wu SS, Vogel WB, Young GC, Duncan PW. Multiple system utilization and mortality for veterans with stroke. Stroke. 2007 Feb;38(2):355–60. doi: 10.1161/01.STR.0000254457.38901.fb.
    1. Wolinsky FD, An H, Liu L, Miller TR, Rosenthal GE. Exploring the association of dual use of the VHA and medicare with mortality: separating the contributions of inpatient and outpatient services. BMC Health Serv Res. 2007 May 9;7(1):1320–2. doi: 10.1186/1472-6963-7-70.
    1. Tarlov E, Lee TA, Weichle TW, Durazo-Arvizu R, Zhang Q, Perrin R, Bentrem D, Hynes DM. Reduced overall and event-free survival among colon cancer patients using dual system care. Cancer Epidemiol Biomarkers Prev. 2012 Oct 11;21(12):2231–41. doi: 10.1158/1055-9965.EPI-12-0548.
    1. Maciejewski ML, Wang V, Burgess JF, Bryson CL, Perkins M, Liu C. The continuity and quality of primary care. Med Care Res Rev. 2013 Jul 17;70(5):497–513. doi: 10.1177/1077558713495454.
    1. Gellad WF, Zhao X, Thorpe CT, Mor MK, Good CB, Fine MJ. Dual use of department of veterans affairs and medicare benefits and use of test strips in veterans with type 2 diabetes mellitus. JAMA Intern Med. 2015 Jan 1;175(1):26–34. doi: 10.1001/jamainternmed.2014.5405.
    1. Taber DJ, Pilch NA, McGillicuddy JW, Bratton CF, Chavin KD, Baliga PK. Improved patient safety and outcomes with a comprehensive interdisciplinary improvement initiative in kidney transplant recipients. Am J Med Qual. 2012 Jul 22;28(2):103–12. doi: 10.1177/1062860612450309.
    1. Musgrave CR, Pilch NA, Taber DJ, Meadows HB, McGillicuddy JW, Chavin KD, Baliga PK. Improving transplant patient safety through pharmacist discharge medication reconciliation. Am J Transplant. 2013 Jan 17;13(3):796–801. doi: 10.1111/ajt.12070.
    1. Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, Bates DW. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. J Am Med Assoc. 1999 Jul 21;282(3):267. doi: 10.1001/jama.282.3.267.
    1. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy. 2002 Feb;22(2):134–47. doi: 10.1592/phco.22.3.134.33551.
    1. Folli HL, Poole RL, Benitz WE, Russo JC. Medication error prevention by clinical pharmacists in two children's hospitals. Pediatrics. 1987;79(5):718–22.
    1. Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003 Sep 22;163(17):2014–73. doi: 10.1111/ajt.12341. doi: 10.1001/archinte.163.17.2014.
    1. Schnipper JL, Kirwin JL, Cotugno MC, Wahlstrom SA, Brown BA, Tarvin E, Kachalia A, Horng M, Roy CL, McKean SC, Bates DW. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006 Mar 13;166(5):565–4. doi: 10.1001/archinte.166.5.565.
    1. Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, Elliott RA, Howard R, Kendrick D, Morris CJ, Prescott RJ, Swanwick G, Franklin M, Putman K, Boyd M, Sheikh A. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012 Apr;379(9823):1310–9. doi: 10.1016/S0140-6736(11)61817-5.
    1. Elliott RA, Putman KD, Franklin M, Annemans L, Verhaeghe N, Eden M, Hayre J, Rodgers S, Sheikh A, Avery AJ. Cost effectiveness of a pharmacist-led information technology intervention for reducing rates of clinically important errors in medicines management in general practices (PINCER) Pharmacoeconomics. 2014 Mar 18;32(6):573–90. doi: 10.1007/s40273-014-0148-8.
    1. Navaneethan SD, Sankarasubbaiyan S, Gross MD, Jeevanantham V, Monk RD. Tacrolimus-associated hypomagnesemia in renal transplant recipients. Transplant Proc. 2006 Jun;38(5):1320–2. doi: 10.1016/j.transproceed.2006.02.077.
    1. Dobbels F, van Damme-Lombaert R, Vanhaecke J, de Geest S. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant. 2005;9(3):381–90. doi: 10.1111/j.1399-3046.2005.00356.x.
    1. Schold JD, Elfadawy N, Buccini LD, Goldfarb DA, Flechner SM, Phelan MP, Poggio ED. Emergency department visits after kidney transplantation. Clin J Am Soc Nephrol. 2016 Mar 24;11(4):674–83. doi: 10.2215/CJN.07950715.
    1. Taber DJ, Pilch NA, McGillicuddy JW, Bratton CF, Lin A, Chavin KD, Baliga PK. Improving the perioperative value of care for vulnerable kidney transplant recipients. J Am Coll Surg. 2013 Apr;216(4):668–76; discussion 676. doi: 10.1016/j.jamcollsurg.2012.12.023.
    1. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: Wiley-Interscience; 2004.
    1. Gebregziabher M, DeSantis SM. Latent class based multiple imputation approach for missing categorical data. J Stat Plan Inference. 2010 Nov;140(11):3252–62. doi: 10.1016/j.jspi.2010.04.020.
    1. Little RJ, Rubin DB. Statistical Analysis with Missing Data. New York: John Wiley and Sons; 2002.
    1. Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Impact of clinical pharmacy services on renal transplant patients' compliance with immunosuppressive medications. Clin Transplant. 2001 Oct;15(5):330–6. doi: 10.1034/j.1399-0012.2001.150505.x.
    1. Chisholm MA, Mulloy LL, Jagadeesan M, Martin BC, DiPiro JT. Effect of clinical pharmacy services on the blood pressure of African-American renal transplant patients. Ethn Dis. 2002;12(3):392–7.
    1. Chisholm-Burns MA, Spivey CA, Zivin JG, Lee JK, Sredzinski E, Tolley EA. Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. Am J Transplant. 2013 Sep;13(9):2364–73. doi: 10.1111/ajt.12341. doi: 10.1111/ajt.12341.
    1. Maldonado AQ, Weeks DL, Bitterman AN, McCleary JA, Seiger TC, Carson RW, Tabon PK, Goroski AL, Ojogho ON. Changing transplant recipient education and inpatient transplant pharmacy practices: a single-center perspective. Am J Health Syst Pharm. 2013 May 15;70(10):900–4. doi: 10.2146/ajhp120254.
    1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004 Aug;4(8):1289–95. doi: 10.1111/j.1600-6143.2004.00515.x.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다